insights_auto
Why is LSTA down 4,59%?
Dive Deeperchevron_right
LSTA:NASDAQ
Lisata Therapeutics, Inc.
1,04 $
arrow_downward
-4,59%(-0,050) 1D
17 նոյ, 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LSTA...
Open
1,08 $
High
1,10 $
Low
1,00 $
Mkt. cap
11,24 մլն
Avg. vol.
135,12 հզր
Volume
246,91 հզր
52-wk high
5,06 $
52-wk low
0,96 $
EPS
-1,64 $
Beta
1,04
Shares outstanding
10,80 մլն
No. of employees
21
Open
1,08 $
High
1,10 $
Low
1,00 $
Mkt. cap
11,24 մլն
Avg. vol.
135,12 հզր
Volume
246,91 հզր
52-wk high
5,06 $
52-wk low
0,96 $
EPS
-1,64 $
Beta
1,04
Shares outstanding
10,80 մլն
No. of employees
21
News stories
From web sources and news partners
ChartMill
·
1 ժամ առաջ
S&P 500 After-Hours Gainers for Nov. 17, 2026
BigGo Finance
·
50 րոպե առաջ
New York Stocks Slip a Day Before Nvidia Earnings; S&P 500, Nasdaq Fall for Fourth Straight Session
FXStreet
·
1 ժամ առաջ
Dow Jones Industrial Average slides on NSA outage, then Nvidia beats
Traders Union
·
2 ժամ առաջ
Ryan Detrick: Technology stocks outperformed S&P 500 while 75 stocks declined
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics, Inc.
CEO-
Employees21
Founded1980
HeadquartersBasking Ridge, Նյու Ջերսի, Միացյալ Նահանգներ
SectorHealth Care
Industry-
Websitelisata.com